Fish Odour Syndrome: Dermetel aims to give patients a breath of fresh air

man with bad odour in elevator with people
© iStock/hoozone

Dermetel is launching two Phase I clinical trials that focus on the rare disease, Trimethylaminuria or more commonly known, fish odour syndrome.

Fish odour syndrome or Trimethylaminuria is an inherent error of metabolism that occurs due to ruptures in the FMO3 gene. The condition causes permanent, life-changing body odour that persists irrespective of impeccable hygiene and a clean diet.

Edit the faulty genes

The first treatment was created by immunologist Dr Tamara Nicolson, PhD. The treatment involves unobtrusive liver surgery that edit’s the faulty genes responsible for the body odour. The surgery paired with weekly enzyme replacement therapy infusions means the patient no longer produces the fish smell.

Oral Supplement

The second treatment involves an oral supplement that involves cutting edge use of Methylophilus Methylotrophus, which is used as a source of nitrogen for growth. The supplement was conceived in-house by a team of microbiology and medical students, with consulting from Dr John Christodoulou, Sydney Medical School, who devised the idea of the supplement and Dr Brian Hanley, PhD of University of California, Davis.

The patient takes between one and five supplements a day, which curbs all odour for a period before another supplement needs to be taken. The medication takes around three days to begin working and enables the patient to lead a more normal life.

Dermetel is running both trials simultaneously in both London, UK and Raleigh, North Carolina, USA, which allows people in both countries to register to take part in the trials and hopefully help improve their lives for the better.

About Dermetel

Dermetel is a non-profit organisation in the United States focused on running programs and services that alleviate dermatologic health disparities. Founded in 2011, the organisation was founded by students for patients worldwide and is now managed by a professional and experienced team.

Dermetel’s two primary areas of interest are in running Phase I to III clinical trials for rare dermatology diseases sold to larger pharmaceutical companies at the start of phase IV and in providing teledermatology free clinic services to disadvantaged, underserved patients.

Furthermore, Dermetel also maintains a secondary commitment to help assist children with rare dermatology diseases develop their self-confidence and make strong friendships.

Click here to find out more about their clinical trials

1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here